Oligodendroglioma Market Insights, Share, Trends, Growth, Pipeline Review, H1 2016 by Radiant Insights
The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Visit Us @ http://www.radiantinsights.com/research/oligodendroglioma-pipeline-review-h1-2016
The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Visit Us @ http://www.radiantinsights.com/research/oligodendroglioma-pipeline-review-h1-2016
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Oligodendroglioma</strong> <strong>Market</strong> <strong>Insights</strong>, Size, <strong>Pipeline</strong><br />
<strong>Review</strong>, <strong>H1</strong> <strong>2016</strong> <strong>by</strong> <strong>Radiant</strong> <strong>Insights</strong><br />
Summary<br />
Global <strong>Market</strong>s Direct's, ‘<strong>Oligodendroglioma</strong> - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong>', provides an overview of the<br />
<strong>Oligodendroglioma</strong> pipeline landscape.<br />
The report provides comprehensive information on the therapeutics under development for<br />
<strong>Oligodendroglioma</strong>, complete with analysis <strong>by</strong> stage of development, drug target, mechanism of action<br />
(MoA), route of administration (RoA) and molecule type. The report also covers the descriptive<br />
pharmacological action of the therapeutics, its complete research and development history and latest<br />
news and press releases. Additionally, the report provides an overview of key players involved in<br />
therapeutic development for <strong>Oligodendroglioma</strong> and features dormant and discontinued projects.<br />
Browse Ongoing Reports @ http://www.radiantinsights.com/research/oligodendroglioma-pipelinereview-h1-<strong>2016</strong><br />
Global <strong>Market</strong>s Direct's report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from Global<br />
<strong>Market</strong>s Direct's proprietary databases, company/university websites, clinical trial registries,<br />
conferences, SEC filings, investor presentations and featured press releases from company/university<br />
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic<br />
review following a stringent set of processes to ensure that all the profiles are updated with the latest<br />
set of information. Additionally, various dynamic tracking processes ensure that the most recent<br />
developments are captured on a real time basis.<br />
The report helps in identifying and tracking emerging players in the market and their portfolios,<br />
enhances decision making capabilities and helps to create effective counter strategies to gain<br />
competitive advantage.<br />
Note*: Certain sections in the report may be removed or altered based on the availability and relevance<br />
of data.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Oligodendroglioma</strong>
- The report reviews pipeline therapeutics for <strong>Oligodendroglioma</strong> <strong>by</strong> companies and<br />
universities/research institutes based on information derived from company and industry-specific<br />
sources<br />
- The report covers pipeline products based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages<br />
- The report features descriptive drug profiles for the pipeline products which includes, product<br />
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental<br />
activities<br />
- The report reviews key players involved <strong>Oligodendroglioma</strong> therapeutics and enlists all their major and<br />
minor projects<br />
- The report assesses <strong>Oligodendroglioma</strong> therapeutics based on drug target, mechanism of action<br />
(MoA), route of administration (RoA) and molecule type<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- The report reviews latest news related to pipeline therapeutics for <strong>Oligodendroglioma</strong><br />
Reasons to Buy<br />
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D<br />
strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Identify and understand important and diverse types of therapeutics under development for<br />
<strong>Oligodendroglioma</strong><br />
- Identify potential new clients or partners in the target demographic<br />
- Develop strategic initiatives <strong>by</strong> understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively <strong>by</strong> identifying key players and it's most promising pipeline<br />
therapeutics<br />
- Devise corrective measures for pipeline projects <strong>by</strong> understanding <strong>Oligodendroglioma</strong> pipeline depth<br />
and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies <strong>by</strong> identifying prospective partners with<br />
the most attractive projects to enhance and expand business potential and Scope<br />
- Modify the therapeutic portfolio <strong>by</strong> identifying discontinued projects and understanding the factors<br />
that drove them from pipeline<br />
Browse More Categories @ http://www.radiantinsights.com/catalogs<br />
Table of Content<br />
Table of Contents 2<br />
List of Tables 5<br />
List of Figures 6<br />
Introduction 7<br />
Global <strong>Market</strong>s Direct Report Coverage 7<br />
<strong>Oligodendroglioma</strong> Overview 8<br />
Therapeutics Development 9<br />
<strong>Pipeline</strong> Products for <strong>Oligodendroglioma</strong> - Overview 9<br />
<strong>Pipeline</strong> Products for <strong>Oligodendroglioma</strong> - Comparative Analysis 10<br />
<strong>Oligodendroglioma</strong> - Therapeutics under Development <strong>by</strong> Companies 11<br />
<strong>Oligodendroglioma</strong> - Therapeutics under Investigation <strong>by</strong> Universities/Institutes 12
<strong>Oligodendroglioma</strong> - <strong>Pipeline</strong> Products Glance 13<br />
Clinical Stage Products 13<br />
Early Stage Products 14<br />
<strong>Oligodendroglioma</strong> - Products under Development <strong>by</strong> Companies 15<br />
<strong>Oligodendroglioma</strong> - Products under Investigation <strong>by</strong> Universities/Institutes 16<br />
<strong>Oligodendroglioma</strong> - Companies Involved in Therapeutics Development 17<br />
Axelar AB 17<br />
Boehringer Ingelheim GmbH 18<br />
Bristol-Myers Squibb Company 19<br />
Cavion LLC 20<br />
Celgene Corporation 21<br />
Celldex Therapeutics, Inc. 22<br />
e-Therapeutics Plc 23<br />
F. Hoffmann-La Roche Ltd. 24<br />
Millennium Pharmaceuticals, Inc. 25<br />
Novartis AG 26<br />
Pfizer Inc. 27<br />
Tocagen Inc. 28<br />
<strong>Oligodendroglioma</strong> - Therapeutics Assessment 29<br />
Assessment <strong>by</strong> Monotherapy Products 29<br />
Assessment <strong>by</strong> Combination Products 30<br />
Assessment <strong>by</strong> Target 31<br />
Assessment <strong>by</strong> Mechanism of Action 33<br />
Assessment <strong>by</strong> Route of Administration 35<br />
Browse Ongoing Reports @ http://www.radiantinsights.com/research/oligodendroglioma-pipelinereview-h1-<strong>2016</strong><br />
About Us:<br />
<strong>Radiant</strong> <strong>Insights</strong> Inc. is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
Contact Details:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, Inc<br />
28 2nd Street,<br />
Suite 3036 San Francisco,<br />
CA 94105 United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Website: http://www.radiantinsights.com/<br />
Email: sales@radiantinsights.com<br />
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com/
Change language